Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-06-14 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于调整2017年股票期权激励计划行权价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the adjustment of the exercise price of its 2017 stock option incentive plan. It details board and supervisory meetings, shareholder approvals, and legal opinions related to the adjustment of stock option exercise prices due to dividend distribution. The document is a formal announcement about a change in the stock option plan terms, not a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on corporate governance and stock option plan adjustments. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock option plans and their adjustments.
2018-06-14 Chinese
独立董事关于第三届董事会第四十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to the 44th meeting of the third board of directors of the company. It references compliance with stock exchange listing rules and company articles, and discusses approval of a change in the company's stock abbreviation. The document is a formal opinion related to board meeting matters, not a full report, financial statement, or announcement of voting results. It is focused on board/management information regarding governance and company decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial data or voting results, so it is not an Annual Report, Voting Results, or Regulatory Filing. Confidence is high due to clear context and content.
2018-06-13 Chinese
关于变更证券简称的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's stock short name (证券简称) from '量子高科' to '量子生物'. It details the date of the change, reasons for the change, and approvals from the board and regulatory authorities. There is no financial data, no report attached or referenced as being published, and no mention of annual or interim reports. The document is a regulatory announcement about a corporate action related to securities identification, not a financial report or management information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-06-13 Chinese
第三届董事会第四十四次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of a board meeting resolution by Quantum Hi-Tech (China) Biological Co., Ltd. It details the decision to change the company's stock short name from 'Quantum Hi-Tech' to 'Quantum Biology' while keeping the stock code unchanged. The document includes voting results and mentions compliance with legal and regulatory requirements. There is no financial data, no mention of annual or quarterly reports, no audit information, and no investor presentation content. It is clearly a Board/Management Information announcement about a corporate governance decision. Therefore, the appropriate classification is 'MANG' (Board/Management Information). The document length is short and focused on a board resolution, not a report or announcement of a report publication.
2018-06-13 Chinese
关于控股股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the release of pledged shares by a major shareholder of the company Quantum Hi-Tech (China) Biological Co., Ltd. It details the number of shares released from pledge, the dates, and the proportion of shares involved. There is no financial report, earnings data, or management discussion. The content focuses on shareholding and capital structure changes related to pledged shares. This fits the category of Share Issue/Capital Change announcements, specifically about share pledge release, which is a capital structure change.
2018-06-12 Chinese
关于实施2017年度权益分派方案后调整发行股份购买资产发行价格和发行数量的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Quantum Hi-Tech (China) Biological Co., Ltd. regarding adjustments to the issuance price and quantity of shares related to a major asset restructuring. It references the completion of the 2017 equity distribution plan and details changes in share issuance price and quantity due to dividend distribution and other corporate actions. The document includes specific dates, share prices, share quantities, and regulatory approval references (China Securities Regulatory Commission approval). The content focuses on the update of share issuance terms following a major asset purchase transaction and equity distribution, which fits the category of Capital/Financing Update (CAP). The document is relatively short (2511 characters) and is not a full financial report but an announcement of changes in capital structure related to share issuance for asset purchase. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-06-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.